3NK Stock Overview
A clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alphamab Oncology Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.22 |
| 52 Week High | HK$1.57 |
| 52 Week Low | HK$0.22 |
| Beta | 0.27 |
| 11 Month Change | -16.03% |
| 3 Month Change | -54.55% |
| 1 Year Change | -75.96% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3NK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.3% | 1.2% | 0.8% |
| 1Y | -76.0% | -16.0% | 6.1% |
Return vs Industry: 3NK underperformed the German Biotechs industry which returned -16% over the past year.
Return vs Market: 3NK underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 3NK volatility | |
|---|---|
| 3NK Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3NK's share price has been volatile over the past 3 months.
Volatility Over Time: 3NK's weekly volatility has increased from 15% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 435 | Ting Xu | www.alphamabonc.com |
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company’s product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders.
Alphamab Oncology Fundamentals Summary
| 3NK fundamental statistics | |
|---|---|
| Market cap | €257.10m |
| Earnings (TTM) | -€26.80m |
| Revenue (TTM) | €27.84m |
9.2x
P/S Ratio-9.6x
P/E RatioIs 3NK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3NK income statement (TTM) | |
|---|---|
| Revenue | CN¥218.77m |
| Cost of Revenue | CN¥55.24m |
| Gross Profit | CN¥163.54m |
| Other Expenses | CN¥374.13m |
| Earnings | -CN¥210.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 74.75% |
| Net Profit Margin | -96.26% |
| Debt/Equity Ratio | 15.0% |
How did 3NK perform over the long term?
See historical performance and comparison